No Data
BrightPath Biotherapeutics: Confirmation letter
BrightPath Biotherapeutics: Half Year Report - Term 22 (2024/04/01 - 2025/03/31)
BrightPath Biothera 1H Parent Loss Y538.00M Vs Loss Y553.00M
BrightPath Biotherapeutics: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [Japanese GAAP] (unconsolidated)
Morinaga Milk, mcdonald's, Toyo Suisan, Eisai (8th) (1429-5463)
※Please note that the above calendar is tentative and subject to change based on the company's convenience. --------------------------------------- November 8th (Fri) <1429> Japan Aqua <1435> RoboHome <143A> Ishin <1450> Tanaka Construction Industry <1451> KHC <1518> Mitsui Matsushima HD <151A> Dai <167A> Ryo
McLeod, Hope and others [Emerging Markets Press Release]
<3622> Net income forecast revised, current fiscal year net income outlook 0.115 billion yen←0.205 billion yen <3900> CLOCK・IT, which handles CloudWorks system integration, acquired shares and became a subsidiary <4594> Brightpass 17th new subscription rights (with revised exercise price clause) significantly exercised, with 1.5 million shares of stock issued from January 1st <4892> Recognized approximately 1.7 billion yen of government grant revenue as non-operating income <6081> AlliedArch consolidated
No Data
No Data